One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid TumorsResults From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
Alison M. Schram, MD; Nicoletta Colombo, MD, PhD; Edward Arrowsmith, MD; et al.
doi : 10.1001/jamaoncol.2022.5218
January 2023, Vol 9, No. 1, Pages 19-151
Avelumab Plus Talazoparib in Patients With Advanced Solid TumorsThe JAVELIN PARP Medley Nonrandomized Controlled Trial
Timothy A. Yap, MBBS, PhD; Aditya Bardia, MD; Michael Dvorkin, MD, PhD; et al.
Association of Machine Learning–Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC
Mehrdad Rakaee, PhD; Elio Adib, MD; Biagio Ricciuti, MD; et al.
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone MetastasesThe FAST-01 Nonrandomized Trial
Anthony E. Mascia, PhD; Emily C. Daugherty, MD; Yongbin Zhang, MS; et al.
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast CancerA Phase 1 Nonrandomized Clinical Trial
Mary L. (Nora) Disis, MD; Katherine A. Guthrie, PhD; Ying Liu, PhD; et al.
Fracture Risk Among Older Cancer Survivors Compared With Older Adults Without a History of Cancer
Erika Rees-Punia, PhD; Christina C. Newton, MSPH; Helen M. Parsons, PhD; et al.
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study
Shuang Hao, MSc, MPH; Andrea Discacciati, PhD; Martin Eklund, PhD; et al.
Inherited Cancer Susceptibility Gene Sequence Variations Among Patients With Appendix Cancer
Andreana N. Holowatyj, PhD, MS; Mary K. Washington, MD, PhD; Sean V. Tavtigian, PhD; et al.
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
Jennifer L. McQuade, MD; Hans Hammers, MD, PhD; Helena Furberg, PhD; et al.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaA Phase 3 Prospective Externally Controlled Cohort Trial
Linda M. Liau, MD, PhD; Keyoumars Ashkan, MD, FRCP, FRCS; Steven Brem, MD; et al.
Association of Residential Racial and Economic Segregation With Cancer Mortality in the US
Lu Zhang, PhD; Rui Gong, PhD; Lu Shi, PhD; et al.
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Ziad Bakouny, MD; Chris Labaki, MD; Punita Grover, MD; et al.
Receipt of Bilateral Mastectomy Among Women With Hereditary Breast Cancer
Sonya Reid, MD; Mya L. Roberson, PhD; Kenna Koehler, MD; et al.
Rates of Routine Cancer Screening and Diagnosis Before vs After the COVID-19 Pandemic
Allison H. Oakes, PhD; Kelly Boyce, MS; Catherine Patton, BS; et al.
Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung CancerA Review
Aakash P. Desai, MD, MPH; Jacob J. Adashek, DO; Joshua E. Reuss, MD; et al.
Preserving Fertility in Women With CancerPractice Strategies
Aubri S. Hoffman, PhD; J. Alejandro Rauh-Hain, MD, MPH; Terri L. Woodard, MD
Combining PARP Inhibitor With Immunotherapy—Does the Promise of Preclinical Data Translate to Clinic?
Rajat Thawani, MD; Shivaani Kummar, MBBS
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy
David L. Rimm, MD, PhD
The First FLASH Clinical Trial—The Journey of a Thousand Miles Begins With 1 Step
Lesley A. Jarvis, MD, PhD; Rongxiao Zhang, PhD; Brian W. Pogue, PhD
Residential Racial and Economic Segregation and Cancer Mortality in the US—Speaking Out on Inequality and Injustice
Victoria L. Seewaldt, MD; Robert A. Winn, MD
Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer
Vera Cappelletti, MSc; Serena Di Cosimo, MD, PhD; Giancarlo Pruneri, MD
Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer—Reply
Paolo Tarantino, MD; Nabihah Tayob, PhD; Sara M. Tolaney, MD, MPH
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer
Aditya N. Halthore, MD; Gerald L. Andriole, MD; Michael Goldstein, MD, PhD
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer
Dallin Busby, MD; Mani Menon, MD; Ashutosh K. Tewari, MBBS, MCh
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer
Laurence Klotz, CM, MD
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply
Neal D. Shore, MD; Matthew R. Cooperberg, MD; Scott A. Tomlins, MD
